http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
New Study Published in ESMO Open Highlights Guardant Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer
-
Guardant Health (GH) Granted FDA Breakthrough Device Designation for Multi-Cancer Detection (MCD) Test
-
FDA Grants Breakthrough Device Designation to Guardant Health’s Shield Multi-Cancer Detection (MCD) Test
-
National Comprehensive Cancer Network (NCCN) Updates Colorectal Cancer Screening Guidelines to Include Shield Blood-Based Screening
-
SERENA-6 Phase III Trial Demonstrates Clinical Value of Guardant360 CDx Test to Detect Emergence of Endocrine Resistance and Inform a Switch in Therapy Before Radiological Disease Progression in Advan
-
In Largest Molecular Residual Disease (MRD) Study in Colon Cancer, Guardant Reveal Testing Prior to Chemotherapy Provides Robust Stratification for Risk of Disease Recurrence and Survival to Enable Ti
-
Guardant Health (GH) announces new features for Guardant 360 Liquid test
-
Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test
-
Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting
-
Guardant Health (GH) adds full suite of IHC testing
-
Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors
-
Guardant Health (GH) Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of Cancer
-
Guardant Health Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of Cancer
-
Guardant Health to Participate in Upcoming Investor Conferences
-
TIME Names Guardant Health Co-CEOs to 2025 TIME100 Health List of the 100 Most Influential People in Global Health This Year
-
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
-
Guardant Health (GH) Presents Data Demonstrating Strong Performance of Shield Multi-Cancer Detection Test Across 10 Tumor Types
-
Guardant Health Presents Data Demonstrating Strong Performance of Shield Multi-Cancer Detection Test Across 10 Tumor Types
-
Guardant Health (GH) Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete View of Cancer
-
Guardant Health Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete View of Cancer
-
Guardant Health (GH) Announces Strategic Collaboration With Pfizer to Support Development and Commercialization of New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform
-
Guardant Health Announces Strategic Collaboration With Pfizer to Support Development and Commercialization of New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform
-
Guardant Health to Present Data Highlighting Advances in Multi-Cancer Detection and Liquid and Tissue Molecular Profiling at AACR
-
Guardant Health to Report First Quarter 2025 Financial Results on April 30, 2025
-
Guardant Health (GH) partners with Bayshore HealthCare to offer testing portfolio in Canada
-
Guardant Health and Bayshore HealthCare Partner to Expand Access to Advanced Precision Oncology Testing in Canada
-
Guardant Health's (GH) Shield Blood Test Now Covered for VA Community Care Beneficiaries
-
Guardant Health’s Shield Blood Test Now Covered for VA Community Care Beneficiaries
-
Guardant Health (GH) Receives ADLT Status From CMS for Shield Blood Test
-
Guardant Health Receives ADLT Status From CMS for Shield Blood Test
-
Guardant Health Joins Forces With Dak Prescott’s Faith Fight Finish Foundation and Feist-Weiller Cancer Center’s Partners in Wellness to Boost Colon Cancer Screening in Underserved Communities
-
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
New Guardant Health/Harris Poll Survey Highlights Patient Fear and Anxiety as Major Barriers to Colorectal Cancer Screening, but Blood Test Option Offers Hope for Change
-
Guardant Health Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook
-
Guardant Health to Participate in Upcoming Investor Conferences
-
Guardant Health to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
-
Guardant Health’s Shield Test Selected by Abu Dhabi Department of Health for Blood-Based Colorectal Cancer Screening Program
-
Guardant Health (GH) to Present Data at ASCO GI Demonstrating the Value of Its Precision Oncology Tools
-
Guardant Health to Present Data at ASCO GI Demonstrating the Value of Its Precision Oncology Tools for Cancer Detection, Treatment Decisions and Therapy Development
-
Guardant Health Receives Medicare Coverage for Guardant Reveal™ on Smart Liquid Biopsy™ Platform for Surveillance Testing in Colorectal Cancer Patients
-
Guardant Health (GH) and ConcertAI Collaborate to Form First Data-As-A-Service That Integrates Clinical and Tumor Profiling Data to Accelerate Cancer Therapy Research and Development
-
Guardant Health, ConcertAI Collaborate to Form First Data-As-A-Service That Integrates Clinical and Tumor Profiling Data to Accelerate Cancer Therapy Research and Development
-
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2024 Results
-
Guardant Health Shield Platform Selected for Inclusion in National Cancer Institute’s Vanguard Study to Evaluate Emerging Technologies for Multi-Cancer Detection
-
Guardant Health to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
-
Meaningful Insights Biotech Analytics (MiBA) and Guardant Health Announce Strategic Partnership to Optimize Use of Biomarker Testing and Data Analytics to Improve Cancer Care
-
COTA and Guardant Health Partner to Advance Precision Oncology Research and Therapy Development with Real-World Clinicogenomic Data and AI Analytics
-
Guardant Health (GH) Announces Collaboration With Boehringer Ingelheim to Develop Companion Diagnostic for Detection of Specific Mutations in Advanced Lung Cancer
-
Guardant Health Announces Collaboration With Boehringer Ingelheim to Develop Companion Diagnostic for Detection of Specific Mutations in Advanced Lung Cancer

